Physician profile
Anthony Detulio
NPI 1205806064
$14,099.61
in general payments reported to CMS, 2019-2025
48 companies · $2,317 in 2025
The $2,317 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,133 · 2020: $1,453 · 2021: $1,632 · 2022: $2,450 · 2023: $2,045 · 2024: $2,070 · 2025: $2,317.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,432.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,432.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,308.78 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,396.68 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $1,081.63 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $990.63 | 2019-2025 | |
| Abbvie INC. | $907.78 | 2019-2025 | Vraylar, Qulipta, Synthroid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $799.02 | 2019-2024 | Xifaxan, Cycloset |
| Glaxosmithkline, LLC. | $777.96 | 2020-2025 | Trelegy Ellipta, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $704.80 | 2019-2025 | Jardiance |
| Abbott Laboratories | $580.96 | 2020-2025 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $561.70 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $561.63 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $433.89 | 2019-2023 | Belsomra, Januvia, Steglatro |
| Amgen INC. | $358.56 | 2020-2025 | Repatha, Otezla, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $344.56 | 2022-2025 | |
| Amarin Pharma, INC. | $267.19 | 2019-2023 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Detulio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.